Diabetes Mellitus Clinical Trial
— ILLUMINATEOfficial title:
Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents
Verified date | January 2012 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular
disease events, when compared to atorvastatin alone, in patients with coronary heart disease
or risk equivalents
Status | Terminated |
Enrollment | 15067 |
Est. completion date | June 2007 |
Est. primary completion date | June 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of coronary heart disease or risk equivalents that place the patient at high risk for cardiovascular disease events Exclusion Criteria: - Women who are pregnant or lactating, or planning to become pregnant. - Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid - Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors - Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Pfizer Investigational Site | Adelaide | South Australia |
Australia | Pfizer Investigational Site | Bedford Park | South Australia |
Australia | Pfizer Investigational Site | Camperdown | |
Australia | Pfizer Investigational Site | Chermside | Queensland |
Australia | Pfizer Investigational Site | Clayton | Victoria |
Australia | Pfizer Investigational Site | Concord | New South Wales |
Australia | Pfizer Investigational Site | Darlinghurst | |
Australia | Pfizer Investigational Site | East Gosford | New South Wales |
Australia | Pfizer Investigational Site | Fitzroy | Victoria |
Australia | Pfizer Investigational Site | Footscray | Victoria |
Australia | Pfizer Investigational Site | Fremantle | Western Australia |
Australia | Pfizer Investigational Site | Geelong | |
Australia | Pfizer Investigational Site | Heidelberg | Victoria |
Australia | Pfizer Investigational Site | Herston | Queensland |
Australia | Pfizer Investigational Site | Joondalup | Western Australia |
Australia | Pfizer Investigational Site | Launceston, Tas | |
Australia | Pfizer Investigational Site | Melbourne | |
Australia | Pfizer Investigational Site | Nedlands | |
Australia | Pfizer Investigational Site | Perth | |
Australia | Pfizer Investigational Site | Prahran | Victoria |
Australia | Pfizer Investigational Site | Southport | |
Australia | Pfizer Investigational Site | St. Leonards | New South Wales |
Australia | Pfizer Investigational Site | Wollongong | New South Wales |
Australia | Pfizer Investigational Site | Woodville | South Australia |
Australia | Pfizer Investigational Site | Woolloongabba | Queensland |
Canada | Pfizer Investigational Site | Calgary | Alberta |
Canada | Pfizer Investigational Site | Cornwall | Ontario |
Canada | Pfizer Investigational Site | Halifax | Nova Scotia |
Canada | Pfizer Investigational Site | Laval | Quebec |
Canada | Pfizer Investigational Site | Montreal | Quebec |
Canada | Pfizer Investigational Site | Newmarket | Ontario |
Canada | Pfizer Investigational Site | Oshawa | Ontario |
Canada | Pfizer Investigational Site | Saint John's | |
Canada | Pfizer Investigational Site | Sainte-foy | Quebec |
Canada | Pfizer Investigational Site | Sarnia | Ontario |
Canada | Pfizer Investigational Site | Scarborough | Ontario |
Canada | Pfizer Investigational Site | Sherbrooke | Quebec |
Canada | Pfizer Investigational Site | Ste-foy | Quebec |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Vancouver | British Columbia |
Canada | Pfizer Investigational Site | Winnipeg | Manitoba |
Netherlands | Pfizer Investigational Site | Amsterdam | |
Netherlands | Pfizer Investigational Site | AN Rotterdam | |
Netherlands | Pfizer Investigational Site | Apeldoorn | |
Netherlands | Pfizer Investigational Site | Arnhem | |
Netherlands | Pfizer Investigational Site | Breda | |
Netherlands | Pfizer Investigational Site | Cappelle aan den IJssel | |
Netherlands | Pfizer Investigational Site | Delft | |
Netherlands | Pfizer Investigational Site | Eindhoven | |
Netherlands | Pfizer Investigational Site | Goes | |
Netherlands | Pfizer Investigational Site | Gouda | |
Netherlands | Pfizer Investigational Site | Groningen | |
Netherlands | Pfizer Investigational Site | Heerlen | |
Netherlands | Pfizer Investigational Site | Hertogenbosch | |
Netherlands | Pfizer Investigational Site | Hoorn | |
Netherlands | Pfizer Investigational Site | Leiden | |
Netherlands | Pfizer Investigational Site | Maastricht | |
Netherlands | Pfizer Investigational Site | Nijmegen | |
Netherlands | Pfizer Investigational Site | Rotterdam | |
Netherlands | Pfizer Investigational Site | Sittard | |
Netherlands | Pfizer Investigational Site | Utrecht | |
Netherlands | Pfizer Investigational Site | Velp | |
Netherlands | Pfizer Investigational Site | Venlo | |
Netherlands | Pfizer Investigational Site | Zoetermeer | |
Spain | Pfizer Investigational Site | Almeria | |
Spain | Pfizer Investigational Site | Barcelona | |
Spain | Pfizer Investigational Site | Ciudad Real | |
Spain | Pfizer Investigational Site | Ferrol | La Coruna |
Spain | Pfizer Investigational Site | Granada | |
Spain | Pfizer Investigational Site | Jerez de La Frontera | Cadiz |
Spain | Pfizer Investigational Site | Madrid | |
Spain | Pfizer Investigational Site | Malaga | |
Spain | Pfizer Investigational Site | Salamanca | |
Spain | Pfizer Investigational Site | San Sebastian | Guipuzcoa |
Spain | Pfizer Investigational Site | Sant Coloma de Gramenet | Barcelona |
Spain | Pfizer Investigational Site | Santander | Cantabria |
Spain | Pfizer Investigational Site | Santiago De Compostela | La Coruña |
Spain | Pfizer Investigational Site | Sevilla | |
Spain | Pfizer Investigational Site | Terrasa | Barcelona |
Spain | Pfizer Investigational Site | Valencia | |
Spain | Pfizer Investigational Site | Zaragoza | |
Sweden | Pfizer Investigational Site | Borås | |
Sweden | Pfizer Investigational Site | Eskilstuna | |
Sweden | Pfizer Investigational Site | Goteborg | |
Sweden | Pfizer Investigational Site | Göteborg | |
Sweden | Pfizer Investigational Site | Hässleholm | |
Sweden | Pfizer Investigational Site | Helsingborg | |
Sweden | Pfizer Investigational Site | Karlshamn | |
Sweden | Pfizer Investigational Site | Koping | |
Sweden | Pfizer Investigational Site | Linköping | |
Sweden | Pfizer Investigational Site | Lulea | |
Sweden | Pfizer Investigational Site | Lund | |
Sweden | Pfizer Investigational Site | Malmo | |
Sweden | Pfizer Investigational Site | Molndal | |
Sweden | Pfizer Investigational Site | Norrkoping | |
Sweden | Pfizer Investigational Site | Ostersund | |
Sweden | Pfizer Investigational Site | Skelleftea | |
Sweden | Pfizer Investigational Site | Stockholm | |
Sweden | Pfizer Investigational Site | Uddevalla | |
Sweden | Pfizer Investigational Site | Uppsala | |
Sweden | Pfizer Investigational Site | Västervik | |
Sweden | Pfizer Investigational Site | Vaxjo | |
United Kingdom | Pfizer Investigational Site | Aberdeen | |
United Kingdom | Pfizer Investigational Site | Bath | |
United Kingdom | Pfizer Investigational Site | Birmingham | |
United Kingdom | Pfizer Investigational Site | Bournemouth | |
United Kingdom | Pfizer Investigational Site | Brighton, East Sussex | |
United Kingdom | Pfizer Investigational Site | Bristol | |
United Kingdom | Pfizer Investigational Site | Cardiff | |
United Kingdom | Pfizer Investigational Site | Chichester | |
United Kingdom | Pfizer Investigational Site | Coventry | |
United Kingdom | Pfizer Investigational Site | Dundee | |
United Kingdom | Pfizer Investigational Site | Edinburgh | |
United Kingdom | Pfizer Investigational Site | Exeter | |
United Kingdom | Pfizer Investigational Site | Glasgow | |
United Kingdom | Pfizer Investigational Site | Glasgow | Scotland |
United Kingdom | Pfizer Investigational Site | Harrow | |
United Kingdom | Pfizer Investigational Site | Leicester | |
United Kingdom | Pfizer Investigational Site | Liverpool | |
United Kingdom | Pfizer Investigational Site | London | |
United Kingdom | Pfizer Investigational Site | Newcastle-upon-Tyne | |
United Kingdom | Pfizer Investigational Site | Romford | |
United Kingdom | Pfizer Investigational Site | Shrewsbury | |
United Kingdom | Pfizer Investigational Site | Warwick | |
United Kingdom | Pfizer Investigational Site | Woolwich | London |
United Kingdom | Pfizer Investigational Site | Wrexham | Clwyd |
United States | Pfizer Investigational Site | Abington | Massachusetts |
United States | Pfizer Investigational Site | Alabaster | Alabama |
United States | Pfizer Investigational Site | Atlanta | Georgia |
United States | Pfizer Investigational Site | Aurora | Illinois |
United States | Pfizer Investigational Site | Baltimore | Maryland |
United States | Pfizer Investigational Site | Baton Rouge | Louisiana |
United States | Pfizer Investigational Site | Beaumont | Texas |
United States | Pfizer Investigational Site | Beaver | Pennsylvania |
United States | Pfizer Investigational Site | Bel Air | Maryland |
United States | Pfizer Investigational Site | Billings | Montana |
United States | Pfizer Investigational Site | Birmingham | Alabama |
United States | Pfizer Investigational Site | Blue Island | Illinois |
United States | Pfizer Investigational Site | Burien | Washington |
United States | Pfizer Investigational Site | Burlington | Vermont |
United States | Pfizer Investigational Site | Butte | Montana |
United States | Pfizer Investigational Site | Chicago | Illinois |
United States | Pfizer Investigational Site | Cincinnati | Ohio |
United States | Pfizer Investigational Site | Clearwater | Florida |
United States | Pfizer Investigational Site | Cleveland | Ohio |
United States | Pfizer Investigational Site | Columbia | Maryland |
United States | Pfizer Investigational Site | Columbus | Ohio |
United States | Pfizer Investigational Site | Concord | New Hampshire |
United States | Pfizer Investigational Site | Coral Gables | Florida |
United States | Pfizer Investigational Site | Covington | Louisiana |
United States | Pfizer Investigational Site | Dallas | Texas |
United States | Pfizer Investigational Site | Davenport | Iowa |
United States | Pfizer Investigational Site | Denver | Colorado |
United States | Pfizer Investigational Site | des Moines | Iowa |
United States | Pfizer Investigational Site | Durham | North Carolina |
United States | Pfizer Investigational Site | Elmer | New Jersey |
United States | Pfizer Investigational Site | Evansville | Indiana |
United States | Pfizer Investigational Site | Fort Meyers | Florida |
United States | Pfizer Investigational Site | Fort Wayne | Indiana |
United States | Pfizer Investigational Site | Fresno | California |
United States | Pfizer Investigational Site | Garden City | New York |
United States | Pfizer Investigational Site | Gilbert | Arizona |
United States | Pfizer Investigational Site | Grand Rapids | Michigan |
United States | Pfizer Investigational Site | Guilford | Connecticut |
United States | Pfizer Investigational Site | Haddon Heights | New Jersey |
United States | Pfizer Investigational Site | Hartford | Connecticut |
United States | Pfizer Investigational Site | Haverhill | Massachusetts |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Iowa City | Iowa |
United States | Pfizer Investigational Site | Jacksonville | Florida |
United States | Pfizer Investigational Site | Jacksonville Beach | Florida |
United States | Pfizer Investigational Site | Kingsport | Tennessee |
United States | Pfizer Investigational Site | Lakeland | Florida |
United States | Pfizer Investigational Site | Las Vegas | Nevada |
United States | Pfizer Investigational Site | Lebanon | New Hampshire |
United States | Pfizer Investigational Site | Longmont | Colorado |
United States | Pfizer Investigational Site | Los Angeles | California |
United States | Pfizer Investigational Site | Louisville | Kentucky |
United States | Pfizer Investigational Site | Manchester | New Hampshire |
United States | Pfizer Investigational Site | Mansfield | Ohio |
United States | Pfizer Investigational Site | Marrero | Louisiana |
United States | Pfizer Investigational Site | Minneapolis | Minnesota |
United States | Pfizer Investigational Site | Modesto | California |
United States | Pfizer Investigational Site | Nashville | Tennessee |
United States | Pfizer Investigational Site | Natick | Massachusetts |
United States | Pfizer Investigational Site | New Brunswick | New Jersey |
United States | Pfizer Investigational Site | New Hyde Park | New York |
United States | Pfizer Investigational Site | Norfolk | Virginia |
United States | Pfizer Investigational Site | Oklahoma City | Oklahoma |
United States | Pfizer Investigational Site | Omaha | Nebraska |
United States | Pfizer Investigational Site | Orlando | Florida |
United States | Pfizer Investigational Site | Papillon | Nebraska |
United States | Pfizer Investigational Site | Pensacola | Florida |
United States | Pfizer Investigational Site | Philadelphia | Pennsylvania |
United States | Pfizer Investigational Site | Phoenix | Arizona |
United States | Pfizer Investigational Site | Plano | Texas |
United States | Pfizer Investigational Site | Port Charlotte | Florida |
United States | Pfizer Investigational Site | Portland | Oregon |
United States | Pfizer Investigational Site | Richmond | Virginia |
United States | Pfizer Investigational Site | Rochester | New York |
United States | Pfizer Investigational Site | Salt Lake City | Utah |
United States | Pfizer Investigational Site | San Antonio | Texas |
United States | Pfizer Investigational Site | San Diego | California |
United States | Pfizer Investigational Site | Sandusky | Ohio |
United States | Pfizer Investigational Site | Santa Rosa | California |
United States | Pfizer Investigational Site | Sarasota | Florida |
United States | Pfizer Investigational Site | Scarborough | Maine |
United States | Pfizer Investigational Site | St. Louis | Missouri |
United States | Pfizer Investigational Site | St. Paul | Minnesota |
United States | Pfizer Investigational Site | Tacoma | Washington |
United States | Pfizer Investigational Site | Toledo | Ohio |
United States | Pfizer Investigational Site | Towson | Maryland |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Tustin | California |
United States | Pfizer Investigational Site | Walnut Creek | California |
United States | Pfizer Investigational Site | Washington | District of Columbia |
United States | Pfizer Investigational Site | West Palm Beach | Florida |
United States | Pfizer Investigational Site | Westminster | Maryland |
United States | Pfizer Investigational Site | Wichita | Kansas |
United States | Pfizer Investigational Site | Winston-salem | North Carolina |
United States | Pfizer Investigational Site | Witchita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Australia, Canada, Netherlands, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The time to first occurrence of a major cardiovascular disease event | |||
Secondary | Various composites of major cardiovascular disease events and other lipid parameters |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |